A food frequency questionnaire was completed at baseline and every 4 years for 61,181 women and 31,797 men who were free of cancer, heart disease, and stroke at baseline. During 24 years of follow-up, those with higher olive oil intake (>½ tablespoon/day) had 14% significantly lower risk of cardiovascular disease (CVD) and 18% lower risk of coronary heart disease (CHD) than nonconsumers. There were no differences in stroke. Replacing 5 g/d of margarine, butter, mayonnaise, or dairy fat with the equivalent amount of olive oil was associated with 5% to 7% lower risk of total CVD and CHD.Conclusion: Higher olive oil intake was associated with lower risk of CHD and CVD in two large prospective cohorts of U.S. men and women. The substitution of margarine, butter, mayonnaise, and dairy fat with olive oil could lead to lower risk of CHD and CVD.Commentary: Many studies from Europe for many years have shown the benefit of olive oil consumption compared with dairy products. Every Thursday night for the last 30 years, my wife cooks spaghetti, meatballs, and Italian bread slathered with butter for dinner (one of the reasons I married her). I balance the health risks of high cholesterol intake by drinking one or two glasses of red wine. By following the recommendations in this article, I may not savor these dinners as much as I used to, unless I develop more of a taste for olive oil. But by doing so, maybe I'll add a few years to enjoy our Thursday night dinners together.
Background: The authors examined the association between colchicine treatment and clinical outcomes in patients with coronary artery disease. Methods: They performed a meta-analysis of randomised controlled trials (RCTs) involving patients with coronary artery disease receiving add-on colchicine to standard treatment compared with standard treatment. They used a mixed-effects Poisson regression model with random intervention effects to estimate the pooled incidence rate ratios (IRR) with 95% CI. Results: Ten RCTs were identified, including 12,819 participants followed up for a median of 6 months. Colchicine was associated with a lower risk of major adverse cardiovascular events (IRR 0.69; 95% CI [0.60–0.79]; number needed to treat for an additional beneficial outcome [NNTB] = 28); MI (IRR 0.77; 95% CI [0.64–0.93]; NNTB = 95) and ischaemic stroke (IRR 0.48; 95% CI [0.30–0.76]; NNTB = 155) and with a higher risk of gastrointestinal adverse events (IRR 1.69; 95% CI [1.12–2.54]; number needed to treat for an additional harmful outcome [NNTH] = 10). Colchicine did not affect all-cause death (IRR 1.09; 95% CI [0.85–1.40]), or cardiovascular death (IRR 0.75; 95% CI [0.51–1.12]), while it was associated with a higher risk of non-cardiovascular death (IRR 1.45; 95% CI [1.04–2.02]; NNTH = 396). Conclusion: The meta-analysis showed that the relative and absolute beneficial treatment effects of colchicine on cardiovascular outcomes outweigh the potential harm for non-cardiovascular mortality. Registration: PROSPERO 2021 CRD42021248874.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.